may 22, 2018 - FDA convened a joint meeting of the Anesthetic
and Analgesic Drug Products Advisory Committee
and the Drug Safety and Risk Management
Advisory Committee to discuss the new drug
application for buprenorphine sublingual spray,
submitted by INSYS Development Company, Inc.,
for the treatment of moderate-to-severe acute
pain where the use of an opioid analgesic
isappropriate.
Added to timeline:
Opioids and the FDA
Date:
